Literature DB >> 11494930

Pap test results. Responding to Bethesda system reports.

T J Colgan1.   

Abstract

OBJECTIVE: To review the adequacy and diagnostic categories of the Bethesda system for reporting Pap test results (cervicovaginal cytology) and summarize management options. QUALITY OF EVIDENCE: The latest research evidence and guidelines from both international and Canadian sources are reviewed. With a few exceptions, good evidence supports particular management approaches for each adequacy statement and diagnostic category. MAIN MESSAGE: Women with unsatisfactory Pap smears should be re-examined and retested. Women with satisfactory smears and a diagnosis of "within normal limits" (WNL) or "benign cellular changes" (BCC) should be retested only at recommended screening intervals. Women with "satisfactory but limited by..." results and a diagnosis of WNL or BCC should have individualized follow up. Women with diagnoses of high-grade squamous intraepithelial lesions, atypical glandular cells of uncertain significance, or malignancy should have further investigation (colposcopy). Optimal management of asymptomatic women with normal cervices and reports of atypical squamous cells of uncertain significance or low-grade squamous intraepithelial lesions is still controversial.
CONCLUSION: Management of women following Pap tests is determined by both the adequacy of the test and diagnoses based on the results.

Entities:  

Mesh:

Year:  2001        PMID: 11494930      PMCID: PMC2018540     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  25 in total

1.  The effect of the quality of Papanicolaou smears on the detection of cytologic abnormalities.

Authors:  M Mintzer; P Curtis; J C Resnick; D Morrell
Journal:  Cancer       Date:  1999-06-25       Impact factor: 6.860

2.  Human papillomavirus testing for primary cervical cancer screening.

Authors:  J Cuzick
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings.

Authors:  J T Cox
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

4.  "ASCUS, rule out HSIL": cytologic features, histologic correlates, and human papillomavirus detection.

Authors:  M E Sherman; S O Tabbara; D R Scott; R J Kurman; A G Glass; M M Manos; R D Burk; B B Rush; M Schiffman
Journal:  Mod Pathol       Date:  1999-04       Impact factor: 7.842

5.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

6.  HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.

Authors:  T C Wright; L Denny; L Kuhn; A Pollack; A Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

Review 7.  Human papillomaviruses and cervical neoplasia: a model for carcinogenesis.

Authors:  M H Stoler
Journal:  Int J Gynecol Pathol       Date:  2000-01       Impact factor: 2.762

8.  Review of the screening history of Alberta women with invasive cervical cancer.

Authors:  G C Stuart; S E McGregor; M A Duggan; J G Nation
Journal:  CMAJ       Date:  1997-09-01       Impact factor: 8.262

9.  The cytologic history of 245 patients developing invasive cervical carcinoma.

Authors:  J A Carmichael; J F Jeffrey; H D Steele; I D Ohlke
Journal:  Am J Obstet Gynecol       Date:  1984-03-01       Impact factor: 8.661

10.  Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

Authors:  M M Manos; W K Kinney; L B Hurley; M E Sherman; J Shieh-Ngai; R J Kurman; J E Ransley; B J Fetterman; J S Hartinger; K M McIntosh; G F Pawlick; R A Hiatt
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.